Form 4: Lexeo Therapeutics CEO Receives Stock Grant
Insider Transaction (Form 4)
Richard Nolan Townsend, Chief Executive Officer and a Director of Lexeo Therapeutics, Inc., reported multiple transactions in common stock on September 24, 2026.
Summary
- Grant/award: acquired 2,306 Common Stock at $2.64 ($6,097) on September 14, 2026; holds 376,778 after (Direct).
- Grant/award: acquired 145,500 Stock Option (right to buy) on September 24, 2026; holds 145,500 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Richard Nolan Townsend — Director, Officer (Chief Executive Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-14 | Grant/award | Common Stock | 2,306 | $3 | $6.1K | 376,778 |
| 2026-09-24 | Grant/award | Stock Option (right to buy) | 145,500 | — | — | 145,500 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-14 | Grant/award (2,306 shares) |
| 2026-09-24 | Grant/award (145,500 shares) |
Keywords
insider transaction, Form 4, LXEO, Lexeo Therapeutics, Inc., neutral, Richard Nolan Townsend
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.